You are here

Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Little Rock, Arkansas, 72205 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hematologic Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Hospitalized male and female patients, 18 years of age or older

- Patients who have leukemia (acute lymphocytic leukemia [ALL], acute myelogenous
leukemia [AML], chronic lymphocytic leukemia [CLL], chronic myelogenous leukemia
[CML]), that is newly diagnosed, who have had initial induction, re-induction, or
intensification chemotherapy or who have had a bone marrow (allogenic, syngeneic, or
autologous) or peripheral blood stem-cell transplant OR Patients with lymphoma,
Hodgkin's disease, multiple myeloma, myelodysplastic syndrome or myelodysplasia
(refractory anemia [RA], refractory anemia with ringed sideroblasts [RARS], refractory
anemia with excess blasts [RAEB], refractory anemia with excess blasts in
transformation to leukemia [RAEB-T], or chronic myelomonocytic leukemia [CMML].

- Fever, defined as an oral temperature of ≥ 37.9°C /100.2°F, a rectal temperature ≥
38.4°C /101.4°F, or a tympanic temperature ≥ 38°C /100.4°F

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- The presence of any clinically acute or chronic disease or condition that, in the
opinion of the investigator, may interfere with the patient's ability to safely comply
with the conditions of the protocol, or could preclude the evaluation of the patient's
response or could make the completion of the therapy unlikely

- Neutropenia associated with syndromes that are not associated with a high risk of
bacterial infection (eg. chronic benign neutropenia or Kostmann's syndrome)

- Neutropenia due to primary bone marrow failure

NCT00044759
Pfizer
Completed
Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now